Amy Wakeham | Vice President of Investor Relations and Corporate Communications |
Mick Farrell | Chief Executive Officer |
Brett Sandercock | Chief Financial Officer |
David Pendarvis | Secretary and Chief Administrative Officer |
James Hollings | President, Sleep and Respiratory Care Business |
Rob Douglas | Chief Operating Officer |
Margaret Kaczor | William Blair & Company |
David Bailey | Macquarie |
Lyanne Harrison | Bank of America Merrill Lynch |
Saul Hadassin | UBS |
Matthew Mishan | KeyBanc Capital Markets |
Andrew Goodsall | MST Macquarie |
Sean Laaman | Morgan Stanley |
Gretel Janu | Credit Suisse |
David Low | J.P. Morgan |
Michael Matson | Needham |
Chris Cooper | Goldman Sachs |
Suraj Kalia | Oppenheimer & Co, Inc |
Welcome to the Q2 Fiscal Year 2021 ResMed Earnings Conference Call. My name is Shentel, and I will be your operator for today's call. At this time, all participants are in listen-only mode. Please note that this conference is being recorded. I will now turn the call over to Amy Wakeham, Vice President of Investor Relations and Corporate Communications.